ZYME
Zymeworks Inc. Common StockNASDAQ
Healthcare • Biotechnology
Factor tilt: Mid-Cap Blend
$29.63+3.11%
Close Nov 6, 2026
- Market cap
- $2.16B
- 1 month
- +17.3%
- 3 months
- +22.6%
- 1 year
- +64.2%
- 52-week range
- $16.46$31.05
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- $2.19Quarter to Sep 30, 2026 · 8 analysts · revenue $221.01M · -4.5% in 30d
- Short interest
- 8.5% of float5.6M shares · settled Oct 15, 2026 · +5.4% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $37.13M
- Net income
- -$149.99M
- Free cash flow
- -$120.04M
- Book value
- $80.37M
- Total debt
- $268.64M
- P/E
- —
- Price / sales
- 58.3×
- Price / book
- 26.9×
- FCF yield
- -5.6%
- Net margin
- -404.0%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Zymeworks Inc. Common Stock
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists
Read more
of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
- Website
- zymeworks.com
- Headquarters
- Middletown, DE, United States
- Employees
- 231
- Listed
- Apr 28, 2017
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 25, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 6, 2026 | $4.6M | -90.6% | 100.0% | -$42.2M | -$45.0M |
| Mar 2026filed May 7, 2026 | $2.4M | -91.1% | -18.2% | -$47.1M | -$44.2M |
| Dec 2025filed Mar 2, 2026 | $2.5M | -91.9% | 32.8% | -$44.2M | -$41.2M |
| Sep 2025filed Nov 6, 2025 | $27.6M | +72.6% | 100.0% | -$22.1M | -$19.6M |
| Jun 2025filed Aug 7, 2025 | $48.7M | +153.2% | — | -$674.0K | $2.3M |
| Mar 2025filed May 8, 2025 | $27.1M | +170.3% | — | -$25.6M | -$22.6M |
| Dec 2024filed Mar 5, 2025 | $31.0M | +83.3% | — | -$22.2M | -$23.5M |
| Sep 2024filed Oct 31, 2024 | $16.0M | -3.1% | — | -$34.2M | -$29.9M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched ZYME. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
5,577,540 shares short
+286,404 shares (+5.4%) vs Sep 30, 2026
8.5% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
5,291,136 shares short
+352,064 shares (+7.1%) vs Sep 15, 2026
8% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
4,939,072 shares short
+214,241 shares (+4.5%) vs Aug 31, 2026
7.3% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
4,724,831 shares short
+186,478 shares (+4.1%) vs Aug 14, 2026
6.9% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
4,538,353 shares short
+431,763 shares (+10.5%) vs Jul 31, 2026
6.7% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
4,106,590 shares short
+4,333 shares (+0.1%) vs Jul 15, 2026
6% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind ZYME’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if ZYME is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
41 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Oct 29, 2026
Smart-money 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: neutral
Last trade: sell 29 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: neutral. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: neutral. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
204 filers reported a long position in ZYME for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
73.1%
of the 68.4M shares 13-F filers reported
Moves vs Q1 2026
2 added5 trimmed
3 unchanged
Net shares held
+0.6%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | EcoR1 Capital, LLC | $600.4M · 23M shares | 23M | Unchanged |
| 2 | Rubric Capital Management LP | $183M · 7M shares | 7M | Unchanged |
| 3 | BlackRock, Inc. | $111.1M · 4.3M shares | 4.3M | -6.7% |
| 4 | PERCEPTIVE ADVISORS LLC | $109.3M · 4.2M shares | 4.2M | +19.2% |
| 5 | BVF INC/IL | $95.4M · 3.6M shares | 3.6M | -2.3% |
| 6 | MORGAN STANLEY | $58.3M · 2.2M shares | 2.2M | -10.1% |
| 7 | BNP Paribas Asset Management Holding S.A. | $46.6M · 1.8M shares | 1.8M | -6.7% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | $40.8M · 1.6M shares | 1.6M | -8.6% |
| 9 | Assenagon Asset Management S.A. | $32.7M · 1.3M shares | 1.3M | +72% |
| 10 | Nextech Invest Ltd. | $29.1M · 1.1M shares | 1.1M | Unchanged |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of ZYME file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| May 15, 2026 | Rubric Capital Management LP13G · passive · amended | 9.49% |
| Apr 15, 2026 | PERCEPTIVE ADVISORS LLC13G · passive | 5.4% |
Get the Full Analysis for ZYME
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.